Fingerprint
Dive into the research topics where Group Rössig is active. These topic labels come from the works of this organisation's members. Together they form a unique fingerprint.
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Profiles
-
Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum
DuBois, S. G., Moreno, L., Anderson, J., Asgharzadeh, S., Bagatell, R., Beck-Popovic, M., Belle, J., Berlanga, P., Bird, N. J., Chesler, L., Durbin, A., Eggert, A., Eilers, M., Federico, S. M., Fischer, M., Gatz, S. A., George, R. E., George, S., Goldsmith, K. C. & Gray, J. & 25 others, , Sept 2025, In: Pediatric Blood and Cancer. 72, 9, e31831.Research output: Contribution to journal › Review article › peer-review
Open Access4 Citations (Scopus) -
B7-H3 in the tumor microenvironment: Implications for CAR T cell therapy in pediatric solid tumors
Jansen, L., Wienke, J., Molkenbur, R., Rossig, C. & Meissner, R., 11 Oct 2025, In: Cancer and Metastasis Reviews. 44, 4, 77.Research output: Contribution to journal › Review article › peer-review
Open Access5 Citations (Scopus) -
Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed
International BFM Study Group (I-BFM) & Innovative Therapies for Children with Cancer (ITCC), and the European Society for Paediatric Oncology (SIOPE), 20 Jan 2024, In: Journal of Clinical Oncology. 42, 3, p. 253-257 5 p.Research output: Contribution to journal › Comment/debate
16 Citations (Scopus)